6,7-Dihydro-5H-pyrimidino<4,5-b><1,4>thiazin | 24241-24-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 6,7-Dihydro-5H-pyrimidino<4,5-b><1,4>thiazin
• 英文别名: 5H,6H,7H-pyrimido[4,5-b][1,4]thiazine；6,7-dihydro-5H-pyrimido[4,5-b][1,4]thiazine
• CAS: 24241-24-5
• 化学式: C₆H₇N₃S
• 分子量: 153.208
• InChiKey: GKMCSBGMOFNEFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 2,4-Diaminopyrimidine compounds useful as immunosuppressants
  申请人：——

  公开号：US20030191307A1

  公开（公告）日：2003-10-09

  Novel compounds according to the formula 1 and pharmaceutically acceptable salts, solvates, or hydrates thereof; wherein each occurrence of A is independently selected from CH or N; X is selected from the group consisting of —CH 2 —, —O—, —NH—, (C 1 -C 6 )alkylamino-, (C 1 -C 6 )alkylaminocarbonylamino-, (C 1 -C 6 )alkylcarbonylamino-, (C 1 -C 6 )alkylsulfonylamino-, phenylsulfonylamino-, carbonyl, —NH—C(O)—, —N(C 1 -C 6 )alkyl-C(O)—, —S(O) y — where y is 0, 1 or 2, and; n in —(CH 2 ) n — is 1, 2 or 3; and R 1 , R 2 , and R 3 are as described herein; pharmaceutical compositions that including these compounds, and methods for the treatment of autoimmune disease, inflammation, allergy, transplant rejection, and other circumstances where administration of an immunosuppressive agent is of therapeutic benefit.

  根据公式1及其药学上可接受的盐、溶剂或水合物，制备了新的化合物；其中A的每次出现独立地选自CH或N；X选自以下群体：—CH2—、—O—、—NH—、(C1-C6)烷基氨基、(C1-C6)烷基氨基甲酰氨基、(C1-C6)烷基羧酰氨基、(C1-C6)烷基磺酰氨基、苯基磺酰氨基、羰基、—NH—C(O)—、—N(C1-C6)烷基-C(O)—、—S(O)y—，其中y为0、1或2，而—( )n—中的n为1、2或3；R1、R2和R3如本文所述；包括这些化合物的药物组合物，以及用于治疗自身免疫性疾病、炎症、过敏、移植排斥以及其他需要免疫抑制剂治疗的情况的方法。
• 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS
  申请人：Pfizer Products Inc.

  公开号：EP1242403B1

  公开（公告）日：2006-01-04
• US7101869B2
  申请人：——

  公开号：US7101869B2

  公开（公告）日：2006-09-05
• [EN] 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS<br/>[FR] COMPOSES DE 2,4-DIAMINOPYRIMIDINE UTILISES COMME IMMUNODEPRESSEURS
  申请人：PFIZER PROD INC

  公开号：WO2001040215A1

  公开（公告）日：2001-06-07

  Novel compounds according to formula (I) and pharmaceutically acceptable salts, solvates, or hydrates thereof; wherein each occurrence of A is independently selected from CH or N; X is selected from the group consisting of -CH2-, -O-, -NH-, (C1-C6)alkylamino-, (C1-C6)alkylaminocarbonylamino-, (C1-C6)alkylcarbonylamino-, (C1-C6)alkylsulfonylamino-, phenylsulfonylamino-, carbonyl, -NH-C(O)-, -N(C1-C6)alkyl-C(O)-, -S(O)y- where y is 0, 1 or 2, and n in-(CH2)n- is 1, 2 or 3; and R?1, R2, and R3¿ are as described herein; pharmaceutical compositions that include these compounds, and methods for the treatment of autoimmune disease, inflammation, allergy, transplant rejection, and other circumstances where administration of an immunosuppressive agent is of therapeutic benefit.